An Early Phase 1 interventional study of Empagliflozin 10 MG in Chronic Kidney Diseases and Pediatric Kidney Disease, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 1 site in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.
Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 15th largest by planned enrollment, is one of 5 that started in 2024, is one of 2 in phase 1, and was the 13th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 19+
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 19–90
Baylor Research Institute · Sites in United States
Ages 18–84
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 20–90
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 12 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 3 · Phase 4 9
First in 2019; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 77 across the 20 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Ann & Robert H Lurie Children's Hospital of Chicago is the lead sponsor of 180 studies on the registry; 27 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Ann & Robert H Lurie Children's Hospital of Chicago has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies testing empagliflozin in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are:
Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care.
Study Procedures Include
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin 10mg daily for 3 months (n=20)
Drug: Empagliflozin 10 MG
Participants will not take empagliflozin (n=20)
Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
Percentage of participants who complete all study procedures
Compared to the number recruited, how many participants complete the study
Time frame: 4 years
Systolic Blood Pressure
In-clinic systolic blood pressure
Time frame: 3 months
Serum N-terminal pro-brain natruetic peptide (NT-proBNP)
Time frame: 3 months
Urine Albumin to Creatinine Ratio (UACr)
Time frame: 3 months
Left Atrial Reservoir Strain
Measuring using echocardiography
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin
Renal Insufficiency, Chronic →
Ann & Robert H Lurie Children's Hospital of Chicago →